external-link icon-resource-website icon-resource-website

COVID-19: Find out about our screening clinic - and note our reduced visitor hours and visitor restrictions

The work of Alfred Health researchers is published in a range of peer reviewed journals.

Search or browse research articles by year, by research area and by publication type.

Publication Details

Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy

Beckman K, O'Callaghan M, Vincent A, Roder D, Millar J, Evans S, McNeil J, Moretti K

(2018), ANZ J Surg, 88(3), e183-188

DOI: 10.1111/ans.13954

Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method

Tsiamis E, Millar J, Baxi S, Borg M, De Ieso P, Elsaleh H, Foroudi F, Higgs B, Holt T, Martin J, Moretti K, Pryor D, Skala M, Evans S

(2018), Radiother Oncol, 128(2), 308-14

DOI: 10.1016/j.radonc.2018.04.017

An integrated system for clinical treatment verification of HDR prostate brachytherapy combining source tracking with pretreatment imaging

Smith RL, Hanlon M, Panettieri V, Millar JL, Matheson B, Haworth A, Franich RD

(2018), Brachytherapy, 17(1), 111-121

DOI: 10.1016/j.brachy.2017.08.004

Quality Indicators for Global Benchmarking of Localized Prostate Cancer Management

Sampurno F, Zheng J, Di Stefano L, Millar JL, Foster C, Fuedea F, Higano C, Hulan H, Mark S, Moore C, Richardson A, Sullivan F, Wenger NS, Wittmann D, Evans S

(2018), J Urol, 200(2), 319-326

DOI: 10.1016/j.juro.2018.02.071

Early-onset baldness and the risk of aggressive prostate cancer: findings from a case-control study

Papa NP, MacInnis RJ, English DR, Bolton D, Davis ID, Lawrentschuk N, Millar JL, Severi G, Hopper JL, Giles GG

(2018), Cancer Causes Control, 29(1), 93-102

DOI: 10.1007/s10552-017-0981-0

Brachytherapy-based radiotherapy with androgen deprivation for management of high-risk prostate cancer - time to reverse the declining trend?

Ong WL, Yaxley JW, Millar JL

(2018), BJU Int, 122 Suppl 5, 43591

DOI: 10.1111/bju.14487

Optimal Treatment for High-Risk Prostate Cancer

Ong WL, Koh TL, Millar J

(2018), JAMA, 320(4), 404-405

DOI: 10.1001/jama.2018.6709

Under-utilisation of high-dose-rate brachytherapy boost in men with intermediate-high risk prostate cancer treated with external beam radiotherapy

Ong WL, Evans SM, Millar JL

(2018), J Med Imaging Radiat Oncol, 62(2), 256-261

DOI: 10.1111/1754-9485.12699

In Regard to Yang et al

Ong WL, Evans S, Millar J

(2018), Int J Radiat Oncol Biol Phys, 100(5), 1294-1295

DOI: 10.1016/j.ijrobp.2018.01.019

Development of Indicators to Assess Quality of Care for Prostate Cancer

Nag N, Millar J, Davis ID, Costello S, Duthie JB, Mark S, Delprado W, Smith D, Pryor D, Galvin D, Sullivan F, Murphy °C, Roder D, Elsaleh H, Currow D, White C, Skala M, Moretti KL, Walker T, De Ieso P, Brooks A, Heathcote P, Frydenberg M, Thavaseelan J, Evans SM

(2018), Eur Urol Focus, 4(1), 57-63

DOI: 10.1016/j.euf.2016.01.016

Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03

MacManus M, Fisher R, Roos D, O'Brien P, Macann A, Davis S, Tsang R, Christie D, McClure B, Joseph D, Jayamohan J, Seymour JF

(2018), J Clin Oncol, 36(29), 2918-2925

DOI: 10.1200/JCO.2018.77.9892

Understanding the Relationship Between Interactive Optimisation and Visual Analytics in the Context of Prostate Brachytherapy

Liu J, Dwyer T, Marriott K, Millar J, Haworth A

(2018), IEEE Trans Vis Comput Graph, 24(1), 319-329

DOI: 10.1109/TVCG.2017.2744418

Radiobiological parameters in a tumour control probability model for prostate cancer LDR brachytherapy

Her EJ, Reynolds HM, Mears C, Williams S, Moorehouse C, Millar JL, Ebert MA, Haworth A

(2018), Phys Med Biol, 63(13), 135011

DOI: 10.1088/1361-6560/aac814

Application of the 'Spiking' method to the measurement of low dose radiation (≤ 1Gy) using alanine dosimeters

Geso M, Ackerly T, Lim SA, Best SP, Gagliardi F, Smith CL

(2018), Appl Radiat Isot, 133, 111-116

DOI: 10.1016/j.apradiso.2018.01.003

Dose response and stability of water equivalent PRESAGE® dosimeters for synchrotron radiation therapy dosimetry

Gagliardi FM, Franich RD, Geso M

(2018), Phys Med Biol, 63(23), 235027

DOI: 10.1088/1361-6560/aaf1f5

Water equivalent PRESAGE® for synchrotron radiation therapy dosimetry

Gagliardi FM, Day L, Poole CM, Franich RD, Geso M

(2018), Med Phys, 45(3), 1255

DOI: 10.1002/mp.12745

Interpolation to define clinical tumor stage in prostate cancer using clinical description of digital rectal examination

Evans SM, Murphy DG, Davis ID, Sengupta S, Borzeshi EZ, Sampurno F, Millar JL

(2018), Asia Pac J Clin Oncol, 14(5), e412-19

DOI: 10.1111/ajco.12875

Active surveillance of men with low risk prostate cancer: evidence from the Prostate Cancer Outcomes Registry-Victoria

Evans MA, Millar JL, Earnest A, Frydenberg M, Davis ID, Murphy DG, Kearns PA, Evans SM

(2018), Med J Aust, 208(10), 439-443

DOI: 10.5694/mja17.00559

Patterns of care and outcomes for men diagnosed with prostate cancer in Victoria: an update

Wang LL, Begashaw K, Evans M, Earnest A, Evans SM, Millar JL, Murphy DG, Moon D

(2018), ANZ J Surg, 88(10), 1037-1042

DOI: 10.1111/ans.14722

Transition Points for the Routine Integration of Palliative Care in Patients With Advanced Cancer

Collins A, Sundararajan V, Burchell J, Millar J, McLachlan SA, Krishnasamy M, Le BH, Mileshkin L, Hudson P, Philip J

(2018), J Pain Symptom Manage, 56(2), 185-194

DOI: 10.1016/j.jpainsymman.2018.03.022